Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 93

Results For "NAL"

6627 News Found

Ascletis Pharma reports positive Phase I results for oral IL-17 inhibitor
Clinical Trials | December 17, 2025

Ascletis Pharma reports positive Phase I results for oral IL-17 inhibitor

The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants


FDA nod to first oral single-dose treatment for gonorrhea
Drug Approval | December 16, 2025

FDA nod to first oral single-dose treatment for gonorrhea

The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership


Accenture invests in Ryght AI to revolutionize clinical trials
Digitisation | December 16, 2025

Accenture invests in Ryght AI to revolutionize clinical trials

Ryght AI tackles these hurdles with its AI Site Twin platform


Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary
News | December 16, 2025

Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary

The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products


Shelter Pharma launches D3 cure capsules
News | December 16, 2025

Shelter Pharma launches D3 cure capsules

This launch is part of the company's strategy to expand its nutraceutical portfolio


Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow
People | December 16, 2025

Godavari Biorefineries ED Sangeeta Srivastava named BRSI Honorary Fellow

Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation


Pharma overhaul: EMA hails “Once-in-a-Generation” reform
Policy | December 16, 2025

Pharma overhaul: EMA hails “Once-in-a-Generation” reform

The reform is set to modernise how medicines are developed, authorised, and made available across the EU


Sanofi secures two breakthrough nods in China for rare blood disorders
News | December 16, 2025

Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia